Trials / Completed
CompletedNCT03315260
Treatment Satisfaction With Ra-223 in Japan
Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 85 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to answer the research question: Are Japanese bone metastatic CRPC patients satisfied with their Ra-223 treatment, and what factors drive such satisfaction? It also aims to determine patient anxiety regarding prostate cancer while on treatment with Ra-223, and assess the effect on quality of life.
Detailed description
This is a local, Japanese, prospective, longitudinal, observational, company-sponsored, multi-center, single arm study that will describe treatment satisfaction with Ra-223 in 150 bone metastatic CRPC patients on 1st to 3rd line CRPC therapy. All outcomes will be obtained using PRO questionnaires at 4 time points: before treatment, during treatment, and at 1-month after the last treatment cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium-223 dichloride (Xofigo, BAY88-8223) | Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan) |
Timeline
- Start date
- 2019-04-11
- Primary completion
- 2022-12-01
- Completion
- 2023-03-20
- First posted
- 2017-10-20
- Last updated
- 2024-02-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03315260. Inclusion in this directory is not an endorsement.